A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-07-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartulnventricularsubject hasleft
  Phrases that lowered it: drugsadministrationmultipleessentialstudy period
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 5.7% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 32.1% (raises risk) · Drug's FDA history
• Phase: 1/2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 29 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 386 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.7% (raises risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 69 (lowers risk) · Who can join
• Blinding: none (raises risk) · Design
• Drug's FAERS reports before start: 14652 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia NCT02236013 · started 2015 · scored riskier than 69% of active trials completed
• A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy NCT02752035 · started 2016 · scored riskier than 73% of active trials completed
• A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients NCT03720366 · started 2018 · scored riskier than 76% of active trials completed
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation NCT02577406 · started 2015 · scored riskier than 92% of active trials completed
• A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) NCT03730012 · started 2019 · scored riskier than 88% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.